Quince Therapeutics receives two Nasdaq deficiency notices with 180-day cure periods

Quince Therapeutics, Inc.

Bid Price Notice: common stock closing bid below $1.00 for 30 consecutive business days; cure by Sept 14, 2026.
MVLS Notice: market value of listed securities below $50M for 30 consecutive business days; cure by Sept 14, 2026.
To regain compliance, bid price must close at $1+ for 10 consecutive days, or MVLS at $50M+ for 10 consecutive days.
If not cured by deadline, company may transfer to Nasdaq Capital Market or face delisting.
Stock continues trading on Nasdaq under symbol QNCX during cure period.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.